Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma.
about
Raf family kinases: old dogs have learned new tricksMicroRNA-21 targets Sprouty2 and promotes cellular outgrowthsExpression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomasTargeted therapy for hepatocellular carcinoma: novel agents on the horizonHECT domain-containing E3 ubiquitin ligase Nedd4 interacts with and ubiquitinates Sprouty2.Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.The expression of the Sprouty 1 protein inversely correlates with growth, proliferation, migration and invasion of ovarian cancer cellsThe developing story of Sprouty and cancer.Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapyFunctional interaction between Env oncogene from Jaagsiekte sheep retrovirus and tumor suppressor Sprouty2.Correlation analysis of liver tumor-associated genes with liver regenerationHypoxia and nickel inhibit histone demethylase JMJD1A and repress Spry2 expression in human bronchial epithelial BEAS-2B cells.ErbB2 stabilizes epidermal growth factor receptor (EGFR) expression via Erk and Sprouty2 in extracellular matrix-detached cellsExpression and functional role of sprouty-2 in breast morphogenesis.Liver cancer: Targeted future optionsSPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferationRoles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing FieldSprouty is a cytoplasmic target of adenoviral E1A oncoproteins to regulate the receptor tyrosine kinase signalling pathwayTumor-specifically hypoxia-induced therapy of SPRY1/2 displayed differential therapeutic efficacy for melanoma.Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteinsAnticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selectionEndometrial Cancer and Hypermethylation: Regulation of DNA and MicroRNA by EpigeneticsSprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinomaSprouty is a negative regulator of transforming growth factor β-induced epithelial-to-mesenchymal transition and cataract.Hypoxia inducible factors regulate the transcription of the sprouty2 gene and expression of the sprouty2 proteinFibrosis in the lens. Sprouty regulation of TGFβ-signaling prevents lens EMT leading to cataract.The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control.Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines.Aberrant expression of hSef and Sprouty4 in endometrial adenocarcinoma.ERK MAP kinase in G cell cycle progression and cancer.c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2.Intermolecular interactions of Sprouty proteins and their implications in development and disease.Sprouty1 induces a senescence-associated secretory phenotype by regulating NFκB activity: implications for tumorigenesis.Emerging Raf inhibitors.Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression.Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.Hydrodynamic transfection for generation of novel mouse models for liver cancer research.
P2860
Q24316181-DD142EAB-8C66-4945-8E39-B85BE39E90E0Q24653709-185B4D03-FD55-435F-85F6-CA750AF41170Q24657474-C3ACFC5C-67D0-400F-A61A-072CBC01B081Q27002288-48DA0FAB-C137-45AA-9A76-71A35DD581EBQ33581236-E6537783-E18C-4B02-A008-1E5FF0B2F081Q33750182-1EB5B605-D179-4A6D-ACEC-2A5512CD1B90Q33756953-A76639D5-2F92-4974-B0E4-D1CB6FDA2734Q33962853-0E9933DE-C239-464E-A5D2-72427848EA36Q34016357-609E95F0-DD36-4952-8564-3AB6B61312D9Q34067681-02C7E27F-339D-4EFD-8A60-820FDCEA200AQ34233029-6E7399EB-8F8F-4B51-8E00-CE312CEAC628Q34363873-3E45AF4E-25AB-45C7-8946-A1DCBCA1FFC9Q34452774-91B7AC68-F1AF-46B0-A6CA-D787B8C13F2FQ34662115-AB3F7C67-B817-4026-AE7A-D8EBADA9C2A1Q34695180-CF581D8E-E9BD-4E1A-A836-4EC4D3C9042BQ34704836-6AE3BA2C-0F2F-4F07-8C6D-A68E8EA1623BQ34966603-66545325-C3AE-45F9-88FB-506375FDFBEAQ34996130-352D012F-7DF6-49E8-BB45-0DFF6E34D8D7Q35154608-1653F119-B8E5-49E4-9D09-189CDE1E1451Q35402529-C88EE7E1-F624-42D6-A016-35F8636CA46FQ35604936-03844FB8-064F-4E96-A2AB-112A880749EFQ35677556-619F7073-3A10-4C99-A5AA-D1EF9BF578DFQ35882785-E23AF4EA-391B-4A43-B4E9-B91FA9C01EB9Q36043347-7DFD8295-1723-4439-A759-0D19766EDD73Q36130909-F19E0D3A-12C1-4814-9EA8-234C330CAF8FQ36280143-6A32C4AF-3294-4FDA-9642-9697C8313E7AQ36303720-AAEC7440-88DF-4202-AF3A-408E4B217FD0Q36362544-7AC894DD-3F04-4E3A-A974-54698A0E4131Q36371890-C08DE259-B584-4C5F-A606-4251511D8186Q36454937-94E3165F-9685-4EBD-97BD-D788E3A5D3E0Q36502806-29EEB3A5-7777-4ADE-8C8C-CAC7355D0B8CQ36519437-A461A633-AB91-4992-AB28-B081D938285BQ36947761-E311C4FA-C7E8-4A3D-AC71-37CB2C8E7366Q37402776-CD1AD918-1B92-45B1-B67D-3BA38335D763Q37475506-3458E275-E867-4FEB-9570-914EA8019EC1Q37588717-CAC3026C-1E32-4206-8DE9-7E230A046984Q37706271-9CFBEE36-7C9A-486C-BF4C-9CEAAACB72ACQ37753517-8DC8B5B4-AC54-4B94-944A-BACD5091F770Q37849781-0C16F684-692E-4C58-A94E-4222B856331CQ38183539-952F9B54-C9B2-43E1-8F14-999A7316817B
P2860
Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Sprouty 2, an inhibitor of mit ...... d in hepatocellular carcinoma.
@en
type
label
Sprouty 2, an inhibitor of mit ...... d in hepatocellular carcinoma.
@en
prefLabel
Sprouty 2, an inhibitor of mit ...... d in hepatocellular carcinoma.
@en
P2093
P1433
P1476
Sprouty 2, an inhibitor of mit ...... ed in hepatocellular carcinoma
@en
P2093
Arthur B McKie
Chee Wai Fong
Graeme R Guy
Mei-Sze Chua
Permeen Yusoff
Samuel K S So
Sharon Hee Ming Ling
Ting Ling Lo
Veronica Mason
P304
P356
10.1158/0008-5472.CAN-05-1072
P407
P50
P577
2006-02-01T00:00:00Z